Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
how do you manage atypical adenomatous hyperplasia (AAH) at the margin for 2 sites of the same lobe, in a patient with multiple GGO's s/p wedge resection?
Related Questions
How does metaplastic thymoma histology impact your decision regarding adjuvant radiation?
What are your top takeaways in Thoracic Cancers from ASTRO 2024?
Do you use an LAD constraint in the setting of BID thoracic radiation for SCLC?
For NSCLC patients treated with neoadjuvant chemoimmunotherapy and surgery with ypN2 disease, what factors would cause you to recommend PORT?
How are you incorporating Tumor Treating Fields for locally progressive/metastatic NSCLC, if at all?
How do you talk with your patients regarding radiographic expectations on surveillance CT after lung SBRT?
In a patient who underwent cryoablation for early NSCLC, is there a role for giving preemptive further local therapy?
Would you offer lung SBRT in a patient with Pulmonary Langerhans Cell Histiocytosis (PLCH)?
Given the findings of SUNSET, demonstrating 60 Gy in 8 fractions to be a safe and effective regimen for ultracentral lesions, in what situations would you elect to use a 10 fraction hypofractionated regimen?
Do more fractionated regimens reduce severe toxicity over SBRT in patients with ILD and early-stage NSCLC?
